GPs in Scotland have wider type-2 diabetes treatment choice

GPs in Scotland now have a wider choice of treatments for type-2 diabetes following acceptance of the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin by the Scottish Medicines Consortium (SMC).

SMC accepted sitagliptin to treat type-2 diabetes in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate control of blood sugar. 

It also accepted it for use in combination with a sulphonylurea when diet and exercise plus the highest tolerated dose of sulphonylurea does not provide adequate control of blood sugar and when metformin is not suitable.

The SMC noted that, although sitagliptin is also licensed for use in combination with thiazolidinedione drugs, the manufacturer’s submission related only to the use of sitagliptin in combination with sulphonylureas with or without metformin.

The SMC said it therefore could not recommend the use of sitagliptin in combination with thiazolidinediones.

tom.moberly@haymarket.com

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Most children could be removed from shielded patient list, deputy CMO suggests

Most children could be removed from shielded patient list, deputy CMO suggests

Most children could be removed from the shielded patient list in a future wave of...

GPs can provide some care for shielded patients in clinical settings, NHS England confirms

GPs can provide some care for shielded patients in clinical settings, NHS England confirms

GPs can provide care to shielded patients in 'infection-controlled clinical settings'...

How digital assistants can help patients manage their health and wellbeing

How digital assistants can help patients manage their health and wellbeing

A project in Staffordshire has shown how practices can make use of digital technology...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

Fair death-in-service deal for locums vital before second COVID-19 wave, warns BMA

Fair death-in-service deal for locums vital before second COVID-19 wave, warns BMA

The government must do ‘the right thing’ and secure adequate death-in-service benefits...

GP workload fears over antibody testing rollout for 'no clinical benefit'

GP workload fears over antibody testing rollout for 'no clinical benefit'

GP practices are being contacted by patients asking for antibody tests as the government...